Darzalex (daratumumab)
Multiple Myeloma
Key Facts
About Johnson & Johnson
Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.
View full company profileAbout Genmab
Genmab is a leading biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has established itself as a pioneer in antibody engineering with proprietary technology platforms including DuoBody and HexaBody. Genmab has multiple approved products generating significant revenue and maintains strategic partnerships with major pharmaceutical companies including Janssen, AbbVie, and Roche.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |
| YH29407 | Yuhan | Phase 1 |